+

SG11201406973PA - Complement pathway modulators and uses thereof - Google Patents

Complement pathway modulators and uses thereof

Info

Publication number
SG11201406973PA
SG11201406973PA SG11201406973PA SG11201406973PA SG11201406973PA SG 11201406973P A SG11201406973P A SG 11201406973PA SG 11201406973P A SG11201406973P A SG 11201406973PA SG 11201406973P A SG11201406973P A SG 11201406973PA SG 11201406973P A SG11201406973P A SG 11201406973PA
Authority
SG
Singapore
Prior art keywords
cambridge
institutes
massachusetts
novartis
biomedical research
Prior art date
Application number
SG11201406973PA
Inventor
Christopher Michael Adams
Charles Babu
Jian Ding
Takeru Ehara
Keith Jendza
Nan Ji
Rajeshri Ganesh Karki
Toshio Kawanami
Liang Xue
Nello Mainolfi
James J Powers
Michael H Serrano-Wu
Chun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406973P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201406973PA publication Critical patent/SG11201406973PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 7 November 2013 (07.11.2013) WIPOIPCT (10) International Publication Number WO 2013/164802 A1 (51) International Patent Classification: C07D 403/06 (2006.01) A61P 27/02 (2006.01) C07D 413/06 (2006.01) A61P 37/00 (2006.01) C07D 417/06 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/053546 3 May 2013 (03.05.2013) English (30) Priority Data: 61/642,798 61/782,820 4 May 2012 (04.05.2012) 14 March 2013 (14.03.2013) English US US (71) Applicant (for all designated States except US): NO­ VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). (72) Inventors; and (71) Applicants (for US only): ADAMS, Christopher Mi­ chael [US/US]; Novartis Institutes for BioMedical Re­ search, Inc., 100 Technology Square Cambridge, Cam­ bridge, Massachusetts 02139 (US). BABU, Charles [US/US]; Novartis Institutes for BioMedical Research, Inc., 6201 South Freeway, Fort Worth, Texas 76134 (US). DING, Jian [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square Cambridge, Cam­ bridge, Massachusetts 02139 (US). EHARA, Takeru [JP/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square Cambridge, Cambridge, Mas­ sachusetts 02139 (US). JENDZA, Keith [US/US]; No­ vartis Institutes for BioMedical Research, Inc., 100 Tech­ nology Square Cambridge, Cambridge, Massachusetts 02139 (US). JI, Nan [CN/US]; Novartis Institutes for Bio­ Medical Research, Inc., 100 Technology Square Cam­ bridge, Cambridge, Massachusetts 02139 (US). KARKI, Rajeshri Ganesh [IN/US]; Novartis Institutes for BioMed­ ical Research, Inc., 100 Technology Square Cambridge, Cambridge, Massachusetts 02139 (US). KAWANAMI, Toshio [JP/US]; Novartis Institutes for BioMedical Re­ search, Inc., 100 Technology Square Cambridge, Cam­ bridge, Massachusetts 02139 (US). XUE, Liang [US/US]; Novartis Institutes for BioMedical Research, Inc., 6201 South Freeway, Fort Worth, Texas 76134 (US). MAIN- OLFI, Nello [IT/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square Cambridge, Cam­ bridge, Massachusetts 02139 (US). POWERS, James J. [US/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square Cambridge, Cambridge, Mas­ sachusetts 02139 (US). SERRANO-WU, Michael H. [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square Cambridge, Cambridge, Mas- [Continued on next page] (54) Title: COMPLEMENT PATHWAY MODULATORS AND USES THEREOF CJ o 00 •t (57) Abstract: The present invention provides a compound of formula I: (I) a method for manufac­ turing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. (I) WO 2013/164802 A11 lllll llllllll II llllll III lllll lllll lllll III III III lllll lllll lllll llll llll lllll lllllll llll llll sachusetts 02139 (US). ZHANG, Chun [CN/US]; No­ vartis Institutes for BioMedical Research, Inc., 100 Tech­ nology Square Cambridge, Cambridge, Massachusetts 02139 (US). (74) Common Representative: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201406973PA 2012-05-04 2013-05-03 Complement pathway modulators and uses thereof SG11201406973PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642798P 2012-05-04 2012-05-04
US201361782820P 2013-03-14 2013-03-14
PCT/IB2013/053546 WO2013164802A1 (en) 2012-05-04 2013-05-03 Complement pathway modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201406973PA true SG11201406973PA (en) 2014-12-30

Family

ID=48626502

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406973PA SG11201406973PA (en) 2012-05-04 2013-05-03 Complement pathway modulators and uses thereof

Country Status (25)

Country Link
EP (1) EP2855456B1 (en)
JP (1) JP6180514B2 (en)
KR (1) KR20150003903A (en)
CN (1) CN104603127B (en)
AP (1) AP2014008040A0 (en)
AR (1) AR090945A1 (en)
AU (1) AU2013255470B2 (en)
BR (1) BR112014027359A2 (en)
CA (1) CA2872000A1 (en)
CL (1) CL2014002919A1 (en)
CR (1) CR20140508A (en)
EA (1) EA027113B1 (en)
ES (1) ES2630079T3 (en)
HK (1) HK1206017A1 (en)
IL (1) IL235362A0 (en)
MX (1) MX2014013428A (en)
PE (1) PE20150623A1 (en)
PH (1) PH12014502462A1 (en)
PL (1) PL2855456T3 (en)
PT (1) PT2855456T (en)
SG (1) SG11201406973PA (en)
TN (1) TN2014000449A1 (en)
TW (1) TW201348199A (en)
UY (1) UY34781A (en)
WO (1) WO2013164802A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229003B (en) * 2013-03-14 2017-03-15 诺华股份有限公司 2- (1H-indol-4-ylmethyl) -3H-imidazo [4,5-B ] pyridine-6-carbonitrile derivatives as complement factor B inhibitors for the treatment of ophthalmic diseases
JO3425B1 (en) * 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
CN105849090A (en) * 2013-10-30 2016-08-10 诺华股份有限公司 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
CN103755622A (en) * 2013-12-25 2014-04-30 华东理工大学 Method for synthesizing 4,5,6-7-D4indole-3-acetic acid
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
TWI854164B (en) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 Benzopyrazole compounds and analogues thereof
KR20190036520A (en) 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 Quinazoline and indole compounds for the treatment of medical disorders
EP3985002B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TWI873092B (en) * 2018-04-06 2025-02-21 美商百歐克斯製藥公司 Substituted benzofuran, benzopyrrole,benzothiophene, and structurally related complement inhibitors
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (en) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド Macrocyclic compounds for the treatment of medical disorders
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
WO2021168320A1 (en) 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
EP4132650B1 (en) * 2020-04-07 2024-06-12 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2022028507A1 (en) 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 Heterocyclic compound, preparation method therefor and use thereof
MX2023001517A (en) 2020-08-07 2023-03-06 Shanghai Meiyue Biotech Dev Co Ltd Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof.
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIATED DISORDERS
TWI843416B (en) 2022-01-26 2024-05-21 大陸商上海美悦生物科技發展有限公司 Salt form and crystal form of complement factor b inhibitor and preparation method and use thereof
EP4504699A1 (en) * 2022-04-01 2025-02-12 Novartis AG Complement factor b inhibitors and uses thereof
WO2024099458A1 (en) 2022-11-11 2024-05-16 上海医药工业研究院有限公司 Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
WO2024141011A1 (en) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 Complement factor b inhibitor, pharmaceutical composition and use thereof
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8420919D0 (en) * 1984-08-17 1984-09-19 Beecham Group Plc Compounds
DE19545464A1 (en) * 1995-12-06 1997-06-12 Bayer Ag Benzimidazole isoindolenine dyes
ATE375156T1 (en) * 2000-01-17 2007-10-15 Teijin Pharma Ltd BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
US7488752B2 (en) * 2004-10-08 2009-02-10 Schering Corporation Thrombin receptor antagonists
WO2007034277A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
CN101484420B (en) * 2006-07-03 2014-04-30 比奥维特罗姆上市公司 Indoles as 5-HT6 modulators
JO3265B1 (en) * 2008-12-09 2018-09-16 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
PL2381778T3 (en) * 2008-12-22 2017-01-31 Chemocentryx, Inc. C5ar antagonists
AU2010216239B2 (en) * 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

Also Published As

Publication number Publication date
JP6180514B2 (en) 2017-08-16
AR090945A1 (en) 2014-12-17
IL235362A0 (en) 2014-12-31
UY34781A (en) 2013-12-31
EP2855456A1 (en) 2015-04-08
EP2855456B1 (en) 2017-03-29
PE20150623A1 (en) 2015-05-17
TW201348199A (en) 2013-12-01
BR112014027359A2 (en) 2017-07-18
TN2014000449A1 (en) 2016-03-30
CR20140508A (en) 2015-03-13
KR20150003903A (en) 2015-01-09
CA2872000A1 (en) 2013-11-07
AU2013255470B2 (en) 2015-09-17
CN104603127A (en) 2015-05-06
PH12014502462A1 (en) 2014-12-22
EA027113B1 (en) 2017-06-30
ES2630079T3 (en) 2017-08-17
CN104603127B (en) 2016-10-05
PL2855456T3 (en) 2017-09-29
AP2014008040A0 (en) 2014-10-31
EA201492023A1 (en) 2015-03-31
CL2014002919A1 (en) 2015-07-03
PT2855456T (en) 2017-07-10
JP2015515976A (en) 2015-06-04
WO2013164802A1 (en) 2013-11-07
AU2013255470A1 (en) 2014-11-13
MX2014013428A (en) 2015-02-04
HK1206017A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408261UA (en) Syringe
SG11201907846VA (en) Therapeutic rna
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201407115XA (en) Carboxylic acid compounds
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201407537YA (en) Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201806750WA (en) Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载